European Archives - Page 805 of 994 - European Medical Journal

Imanova Receives £1M Award from the MRC To Develop Early Markers of Dementia –The MIND-MAPS Study

London, UK, April 03, 2017 – Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers…

ELCC 2017: Latest News in Lung Cancer

Geneva, Switzerland, May 5-8 2017 – Around 2,000 delegates from across Europe and worldwide will learn about the latest practice-changing science in the…

Low Vitamin D Levels Linked to Ulcerative Colitis Relapse

CLINICAL relapse risk amongst individuals with ulcerative colitis (UC) more common if the levels of vitamin D in the blood are lower than required…

Connection Uncovered Between Gut Bacteria and Patient Behaviour

A POTENTIAL link has been discerned between gut bacteria and behaviour in patients with irritable bowel syndrome (IBS), a common gastrointestinal…

This March, EMJ Supports

This March, EMJ has proudly showcased its support for an assortment of medical campaigns including: Ovarian Cancer Awareness Month, World Kidney Day…

Revolutionising Digital Healthcare within the National Health Service

The National Health Service (NHS) in the UK is set to introduce major changes to the NHS Choices website in the following months, after an increased…

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

Krakow, Poland / Berlin, Germany, March 28, 2017 – Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today…

Focussed Ultrasound for Tumour Destruction

FOCUSSED ultrasound has been suggested as a future therapy for the gentler treatment of tumours of the liver. Already used readily as a diagnostic method…

Harnessing the Liver’s Fat-Burning Power

LIVER cells have been found to have their own ability to burn accumulated fat, according to Swedish researchers. A new clinical trial has been planned…

Pembrolizumab Improves Survival as a Second-Line Treatment for Urothelial Cancer

PEMBROLIZUMAB, a highly selective, humanised monoclonal antibody targeting programmed cell death 1 (PD-1), has a superior safety profile and improved…